About Mursla
Mursla is a company based in London (United Kingdom) founded in 2017. Mursla has raised $547.19 thousand across 2 funding rounds from investors including Future Fund and Scheme Scoop. The company has 9 employees as of January 31, 2022. Mursla offers products and services including Dynamic Biopsy Platform and EvoLiver™ Test. Mursla operates in a competitive market with competitors including Guardant Health, GRAIL, Color, Nautilus Biotechnology and Somalogic, among others.
- Headquarter London, United Kingdom
- Employees 9 as on 31 Jan, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mursla Limited
- Date of Incorporation 12 Apr, 2017
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$547.19 K (USD)
in 2 rounds
-
Latest Funding Round
$53.38 K (USD), Grant
Sep 01, 2020
-
Investors
Future Fund
& 1 more
-
Employee Count
9
as on Jan 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mursla
Mursla offers a comprehensive portfolio of products and services, including Dynamic Biopsy Platform and EvoLiver™ Test.
Non-invasive platform for analyzing blood vesicles to detect cancer early.
Blood test for early liver cancer in high-risk patients with high sensitivity.
People of Mursla
Unlock access to complete
Funding Insights of Mursla
Mursla has successfully raised a total of $547.19K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $53.38 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mursla
Mursla has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Future Fund and Scheme Scoop.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
News and updates on government schemes are provided.
|
Locked | Locked | Locked |
Investor details for Mursla
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mursla
Investment portfolio details for Mursla
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mursla
Detailed financials for Mursla
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mursla Comparisons
Peer comparison for Mursla
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mursla
Mursla operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Color, Nautilus Biotechnology and Somalogic, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
Detailed competitors of Mursla
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mursla
Complete news archive for Mursla
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mursla
Mursla was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Mursla is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Mursla is a funded company, having raised a total of $547.19K across 2 funding rounds to date.
As of Jan 31, 2022, the latest employee count at Mursla is 9.
Mursla was founded in 2017 in London, United Kingdom, and operates in the health technology sector. A diagnostic device is being developed that employs proprietary nanostructures for non-invasive liquid biopsy. Approved protein biomarkers and semiconductor technology are utilized in large panels to enable early cancer detection. Low-cost solutions for diagnostics and personalized medicine are provided through this platform.
Mursla's top competitors include Guardant Health, GRAIL and Somalogic.
Mursla offers Dynamic Biopsy Platform and EvoLiver™ Test.
Mursla has 2 investors. Key investors include Future Fund, and Scheme Scoop.